University of Oxford’s COVID-19 vaccine trial goes well, human trials will be conducted

The COVID-19 vaccine trial is progressing well and will be conducted in humans, according to researchers involved in the development of the new corona vaccine at the University of Oxford in the UK. Professor Andrew Pollard, head of the vaccine steam at the University of Oxford, said: “Clinical research is going very well and we are now launching a study to assess the effectiveness of the vaccine in inducing an immune response in older people and to test whether it can provide protection in a wider population. We are very grateful for the support of the pilot volunteers to help test whether this new vaccine protects humans from pandemic coronaviruses. “

University of Oxford's COVID-19 vaccine trial goes well, human trials will be conducted

Researchers at the University of Oxford say animal tests have been conducted on six rhesus monkeys and have been successful in producing antibodies. The ChAdOx1n CoV-19 vaccine is made from the virus (ChAdOx1), a weakened version of the common cold virus (adenovirus) that infects chimpanzees and has been genetically modified to grow in humans.

Researchers have begun recruiting the COVID-19 vaccine in the next phase of human trials, the first phase of a trial of healthy adult volunteers that began in April and have completed more than 1,000 immunizations, noting that follow-up studies are currently under way.

It is reported that the clinical study at this stage will recruit a total of 10,260 adults and children in the UK. Phase II clinical studies will expand the age range of vaccinated populations to include a small number of older persons and children, including: 56-69 years old; For these groups, the researchers will assess the immune response of people of different ages to the vaccine to see if there is a difference in the degree of immune system response in the elderly or child.

Phase III clinical studies include an assessment of how vaccines play a role in large populations over the age of 18. The team will assess whether the vaccine is effective in preventing people from contracting COVID-19. Adult participants in Phase II and Phase III clinical studies will be randomly assigned one or two doses of ChAdOx1nCoV-19 vaccine, or another licensed vaccine (MenACWY), which will be used as a “control group” for comparison.

To assess the effectiveness of the vaccine, oxford statisticians compared the number of infections in the “control group” with the number of infections in the vaccination group.

It is worth noting that it has been reported recently that monkeys who had received the vaccine were infected with the new coronavirus and showed obvious symptoms. There was no difference in the amount of viral RNA detected from this site in vaccinated monkeys compared to unvaccinated animals. This means that the antibodies produced by the vaccine do not neutralise the virus, but there are indications that it may reduce the severity of the infection.